Insulet Corporation (NASDAQ:PODD) is among the top 10 healthcare equipment stocks favored by hedge funds. Stifel recently adjusted its price target on Insulet Corporation from $370 to $350, maintaining a Buy rating with a potential 45% upside.

Analyst Mathew Blackman downgraded Insulet Corporation from Buy to Hold on January 27, estimating a target price of $294, suggesting over 21% upside potential. Blackman highlighted O5’s positive patient adoption and growth while cautioning about market competition and narrowing advantages.

Insulet Corporation focuses on manufacturing and selling insulin management systems through the Omnipod platform. The company offers the Omnipod Insulin Management System, a disposable tubeless pump designed for insulin-dependent diabetes, with manufacturing facilities in the US, Malaysia, and China.

While Insulet Corporation shows promise as an investment, some AI stocks may offer greater upside potential with lower downside risk. Investors looking for undervalued AI stocks can explore opportunities in the market.

Read more at Yahoo Finance: O5 Adoption Leads to Bullish Views Around Insulet Corporation (PODD)